Latest News for: pi3k

Edit

Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program

The Galveston Daily News 20 Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Mar 20, 2026-- ....
Edit

Frontier Medicines to Present Findings on PI3Kα-RAS Breaker FMC-242 and AI-Powered Frontier™ Platform at AACR ...

The Galveston Daily News 17 Mar 2026
BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Mar 17, 2026-- ....
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Nasdaq Globe Newswire 04 Mar 2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with

The Eagle-Tribune 04 Mar 2026
— Second clinical candidate from HUTCHMED’s next-generation ATTC platform — ... .
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors (Form 6-K) (HUTCHMED (China) Ltd)

Public Technologies 04 Mar 2026
HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors ... The PI3K/AKT/mTOR ("PAM") pathway is a critical intracellular network involved in cell growth, survival, and division.
Edit

HUTCHMED Initiates Global Trial of PI3K/PIKK-EGFR ATTC Candidate HMPL-A580 in Patients with Solid Tumors

Pharmiweb 04 Mar 2026
... HUTCHMED’s second ATTC based on this highly novel PI3K/PIKK inhibitor payload ... The PI3K/AKT/mTOR (“PAM”) pathway is a critical intracellular network involved in cell growth, survival, and division.
Edit

PI3K Inhibitors Market & Clinical Trials Outlook: Evaluating 25+ Drug Candidates Across 20+ Active Companies ...

GetNews 06 Feb 2026
"PI3K Inhibitors Pipeline" ... PI3K Inhibitors ... Among the four PI3K classes, Class IA PI3Ks—particularly the p110α catalytic subunit—are most commonly implicated in oncogenesis ... Learn more about PI3K-targeted therapies through the @.
  • 1

Article Search

tools
×
×
×
×